Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Juan Pablo FriasMelanie J DaviesJulio RosenstockFederico C Pérez ManghiLaura Fernández LandóBrandon K BergmanBing LiuXuewei CuiKatelyn Brownnull nullPublished in: The New England journal of medicine (2021)
In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
Keyphrases